Drug design and identification of potent leads against Mycobacterium tuberculosis thymidine monophosphate kinase by Van Calenbergh, Serge et al.
  
biblio.ugent.be 
 
The UGent Institutional Repository is the electronic archiving and dissemination platform for all 
UGent research publications. Ghent University has implemented a mandate stipulating that all 
academic publications of UGent researchers should be deposited and archived in this repository. 
Except for items where current copyright restrictions apply, these papers are available in Open 
Access. 
 
This item is the archived peer-reviewed author-version of: 
Title: Thymidine monophosphate kinase from Mycobacterium tuberculosis  
Drug design and identification of potent leads  
 
Authors: S. Van Calenbergh, S. Pochet and H. Munier-Lehmann 
 
In: Curr. Top. Med. Chem., 2012, 12, 694-705 
 
 
   
  
  
  
  
  
  
  
  
  
Thymidine monophosphate kinase from Mycobacterium tuberculosis  
Drug design and identification of potent leads  
 
 
 
S. Van Calenbergh1, S. Pochet2 and H. Munier-Lehmann2,
  
* 
  
  
  
  
  
  
  
1 Laboratory for Medicinal Chemistry (FFW), Ghent University, B-9000 Gent, Belgium; 2
  
Institut 
Pasteur, Unité de Chimie Organique, CNRS URA2128, Paris 15, France 
  
  
  
  
  
*Address correspondence to this author at the Institut Pasteur, Unité de Chimie Organique, CNRS URA2128, 
28 Rue du Dr Roux, 75724 Paris cedex 15, France; Tel: (0033) 1 45 68 83 81; Fax: (0033) 1 45 68 84 04; E-
mail: helene.munier-lehmann@pasteur.fr  
  
  
  
 
  
  
 2 
ABSTRACT  
Antiviral chemotherapy often relies on nucleoside analogues, which, once phophorylated by 
intracellular kinases, target viral polymerases and preclude DNA synthesis. In contrast, nucleoside analogues 
are much less explored as antibacterial drugs. TMPKmt, which is essential to DNA replication, was selected as 
a promising target for inhibitor design. This review will describe how stepwise modifications of the enzyme’s 
substrate, guided by the feedback of the enzyme assays as well as crystallographic information, proved a 
valuable approach to produce potent TMPKmt inhibitors, some of which were also capable to inhibit bacterial 
growth. Perhaps more importantly, some of the reported thymidine analogues also represent valuable tools to 
better understand the structure and the mechanism of this intriguing enzyme. 
 
 
INTRODUCTION  
Once nearly vanquished by antibiotics, at least in the developed world, tuberculosis (TB) resurged in 
the late 1980’s and now kills more than 2 million people a year – second only to AIDS among infectious 
diseases. Thirty million people are at risk of dying from TB in the next 10 years, most of them living in Africa [1]. 
Mycobacterium tuberculosis, the causative agent of TB, is a slow-growing bacillus, primarily transmitted via the 
respiratory route, mostly causing pulmonary TB. Estimates are that one third of the world’s population is 
infected with this tenacious and remarkably successful pathogen, but infection usually does not lead to the 
active disease. Reactivation of this latent infection can be caused by immunodeficiency, HIV infection, use of 
corticosteroids, aging, alcohol and drug abuse. In HIV infected patients, TB has become the main cause of 
death. Next to HIV-infection, demographic factors, socio-economic trends and the neglected TB control in many 
countries caused this vast epidemic.  
The increasing problem of MDR-TB [2] and the lack of an effective vaccine [3] make the development 
of new drugs, that not only act against drug-resistant TB, but also shorten the lengthy therapy, a global 
emergency [4, 5]. In developing new TB drugs, it is crucial to determine which targets in the tubercle bacillus 
are drugable. The complete genome sequence of the M. tuberculosis H37Rv strain has been recently 
determined [6] and analyzed. This milestone, in concert with mycobacterial genetic tools, has greatly facilitated 
the identification of targets involved in bacterial growth, metabolism and viability, whose inactivation will lead to 
bacterial death or inability to persist [7, 8].  
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In this review we will focus on a housekeeping enzyme, namely thymidine monophosphate kinase 
(TMPK) from M. tuberculosis (TMPKmt). This enzyme is part of the nucleotide biosynthesis, which is a 
cornerstone target for antiviral and cancer chemotherapy. Different approaches for the development of 
inhibitors of TMPKmt as potential leads for new antimycobacterial drugs will be described.  
 
TMPKmt 
An attractive target  
Thymidine monophosphate kinase (TMPK, also called ATP:dTMP phosphotransferase or thymidylate kinase) 
belongs to the nucleoside monophosphate kinases (NMPKs) family [9]. It catalyses the reversible 
phosphorylation of thymidine monophosphate (dTMP) to thymidine diphosphate (dTDP) utilizing ATP as its 
preferred phosphoryl donor. Situated at the junction of the de novo and salvage pathways for the synthesis of 
thymidine triphosphate (dTTP), TMPK is the last specific enzyme in these pathways. This enzyme is 
indispensable for growth and survival and, therefore, represents a promising target for developing new TB 
drugs. With experiments using a cdc8 mutant of Saccharomyces cerevisiae, deficient in TMPK, Jong et al. 
proved that yeast TMPK (TMPKy) is essential for DNA replication and thus for cellular growth [10]. 
Although the global folding of TMPKmt [11] is similar to that of other TMPKs, the configuration of its active site 
is unique. Moreover, the enzyme possesses peculiar properties such as AZT-MP being a competitive inhibitor 
[12], suggesting that selective blocking of the bacterial DNA synthesis should be feasible. The latter could also 
be achieved upon incorporation of modified nucleoside triphosphates acting as chain terminators of forming 
DNA. As phosphorylated derivatives are not membrane permeable, nucleotides should preferably be delivered 
as their nucleoside precusors, which are then converted to their phosphorylated counterparts by intracellular 
kinases. This is the case for AZT or other nucleoside analogs used in the HIV therapy. The first phosphorylation 
step is achieved by thymidine kinase (TK) which phosphorylates thymidine (dT) to dTMP. For mycobacteria, 
neither a gene coding for a TK has been identified in the genome of different mycobacteria species [6, 13-15] 
nor any TK activity in crude extracts [16]. However, dT as well as other 5’-modified analogs (5’-azido- or 5’-
amino-5'-deoxy-thymidine) were found to be competitive inhibitors of TMPKmt with affinities in the same range 
as for dTMP [17], indicating that unphosphorylated nucleoside analogs could act directly on the enzyme without 
any metabolic processing, thereby making TMPKmt an attractive target for antituberculosis drugs.  
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Catalytic properties of TMPKmt  
TMPKmt has a broad specificity for nucleoside triphosphates as phosphate donors, and as expected a very 
narrow one for nucleoside monophosphates as phosphate acceptors [12]. This is a general feature of TMPKs 
and other members of the NMPK family [9]. However, TMPK from Plasmodium falciparum has been recently 
described as a notable exception [18]: this enzyme is able to phosphorylate not only pyrimidine (dTMP, dUMP) 
but also purine (dGMP, dIMP and GMP) nucleotides. The catalytic activity of TMPKmt is low [12] compared to 
TMPK from Escherichia coli (TMPKec) and TMPKy, and TMPKmt shows a high resistance to thermal 
denaturation. On the other hand, the Km
 
 values for dTMP and ATP lie in the same order of magnitude for 
TMPKmt, human TMPK (TMPKh), TMPKec and TMPKy (see Table 1).  
TMPK Km
(mM) 
ATP Km
(µM) 
dTMP Vm
(µmole/min/mg 
of protein) 
ATP,dTMP k
(s
cat 
-1
M. tuberculosis  
) 
0.1 4.5 13 4.5 
E. coli  0.04 15 50 10.5 
Yeast  0.19 9 84 35 
Human  0.03 5 3 1.6 
 
Table 1. Kinetic parameters for natural substrates of TMPKy [19], TMPKmt, TMPKec, and TMPKh [12]. 
 
X-ray structures of TMPKmt  
TMPKmt has been crystallized for the first time as a complex with its natural substrate dTMP [11]. It is a 
homodimer, each monomer of 214 residues being composed of nine α-helices surrounding a five-stranded β-
sheet core. This global folding is similar to that of other TMPKs, despite the low similarity of their primary 
sequences: 26%, 25% and 22% sequence identity over about 200 aligned residues with TMPKec, TMPKy and 
TMPKh respectively.  
Three regions contain the essential residues for the catalytic activity of TMPKmt (Fig. 1): 
- the P-loop motif [20] (residues 7-14, GlyX1X2X3X4GlyLysX5) controls the positioning of the 
phosphoryl groups of the phosphate donor. It binds and positions the α- and β-phosphoryl groups of ATP 
through interactions between amide backbone hydrogens and phosphate oxygen atoms. Unique to TMPKs is 
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an interaction between the P-loop and the phosphoryl acceptor dTMP. This interaction is achieved through a 
hydrogen bond between the 3’-hydroxyl group of dTMP and a carboxylic acid residue at position X2 
- the DR(Y/H/F) motif is a loop containing a strictly conserved arginine residue, acting as a clip which 
favorably orients the phosphoryl donor and acceptor via an interaction with the phosphate group of dTMP and 
the γ-phosphate of ATP.  
of the P-
loop motif (D9 in TMPKmt). The exact function of this acidic amino acid (D14 in TMPKy, D15 in TMPKh, and 
E12 in TMPKec) which played a key role in initial efforts to design inhibitors, is still unclear but it seems to be 
crucial for the catalytic mechanism of TMPK as any mutation of this residue in either TMPKy or TMPKh 
abolishes the phosphoryl transfer activity [21].  
- the LID region (residues 147-159) as in all NMPKs is a flexible stretch that undergoes substantial 
conformational changes: a transition from a coil to a helical conformation in TMPKy when ATP becomes bound 
[19]. In most NMPKs, this closure of the LID region brings catalytic arginines to the reaction centre. Eukaryotic 
TMPKs deviate from this paradigm in that they lack positively charged residues in the LID region. This features 
led to a categorization of TMPKs into two types [22]. Type I TMPKs (e.g. TMPKy and TMPKh) have, in addition 
to the invariant lysine (K19 in TMPKh), a basic residue (arginine) around position 16 in their P-loop sequence 
that can interact with the γ-phosphate of ATP and lack such a positively charged residue in the LID region. 
Type II TMPKs (e.g. TMPKec) have a glycine residue at that place in the P-loop and one additional basic 
residue in the LID region that interacts with ATP (R153 in TMPKec). TMPKmt displays a configuration 
essentially representative of type II TMPKs, the LID region comprising a series of basic residues (R149, R151, 
R153 and R156) and the P-loop having the usual glycine residue (G10) at position X3. However, a peculiar 
additional basic residue, R14, is found at position X5
 
in the P-loop, partly reminiscent of type I TMPKs, but 
unique among all TMPKs. Another main difference concerns the LID closure, which is, for TMPKmt, not due to 
ATP binding but to the binding of a Mg2+
 
 ion in the dTMP-binding site [23].  
 
                _ P-loop _ 
mt ------MLIAIEGVDGAGKRTLVEKLSGAFRAAG-RSVATLAFPRYGQSVAADIAAEALHGEH-   56 
sc MMG-RGKLILIEGLDRTGKTTQCNILYKKLQP----NCKLLKFPER-STRIGGLINEYLTDD--   56 
h  MAARRGALIVLEGVDRAGKSTQSRKLVEALCAAGHR-AELLRFPER-STEIGKLLSSYLQKK--   60 
ec ---MRSKYIVIEGLEGAGKTTARNVVVETLEQLGIRDMVFTREPG--GTQLAEKLRSLLLDIKS   59 
          __β1__       ____α1____        __β2__       ____α2______ 
 *** 
mt -GDLASSVYAMATLFALDRAGAVHTIQGLCRGY-DVVILDRYVASNAAYSAARLHENAAGKAA   117 
sc --SFQLSDQAIHLLFSANRWEIVDKIKKDLLEG-KNIVMDRYVYSGVAYSAA---KGTNGMDL   113 
h  --SD-VEDHSVHLLFSANRWEQVPLIKEKLSQG-VTLVVDRYAFSGVAFTGA---K-EN-FSL   114 
ec VGDEVITDKAEVLMFYAARVQLVETVIKPALANGTWVIGDRHDLSTQAYQGG--GRG---IDQ   117 
        ______α3______  ____α4____   __β3__   ____α5____ 
 
                               ______ Lid region ____ 
mt AWVQRIEFARLGLPKPDWQVLLAVSAELAGERSRGR----------AQRDPGRARDNYER-DA   169 
sc DWCLQPD---VGLLKPDLTLFLSTQ-----------DVDNNAEKSG------FGDERYE--TV   154 
h  DWCKQPD---VGLPKPDLVLFLQLQ-----------LAD-AAKRGA------FGHERYE--NG   154 
ec HMLATLRDAVLGDFRPDLTLYLDVTPEVGLKRARAR---------G-------ELDRIEQESF   164 
    __α6__          __β4__                                       
 
 
mt ELQQRTGAVYAELAAQGW---GGRWLVVGAD-VDPGRLAATLAPPDVPS---------------  214 
sc KFQEKVKQTFMKLLDKEIRKGDESITIVDVT-NKGIQEVEALIWQIVEPVLSTHIDHDKFSFF-  216 
h  AFQERALRCFHQLM------KDTTLNWKMVDASKSIEAVHEDIRVLSEDAIRTATEKPLGELWK  212 
ec DFFNRTRARYLELAAQ-----DKSIHTIDAT-QPLEAVMDAIRTTVTHWVKELDA---------  213 
    ______α7______           __β5__     ______α8______ 
 
Fig. (1). Structure-based sequence alignment of TMPKmt (mt), TMPKy (sc), TMPKh (h) and TMPKec (ec). The secondary 
structural elements of TMPKy as well as the P-loop and the LID domain are shown under and above the alignment, 
respectively. The LID domains of TMPKy and TMPKh were not aligned to those of TMPKmt and TMPKec as their 
backbone conformations differ greatly and do not superimpose. The DR(Y/H/F) motif is marked by asterisks. Underlined 
and bold residues are mentioned in the text.  
Like other NMPKs, TMPKmt undergoes large conformational changes upon substrate binding. One can 
distinguish between the open conformation, observed without substrate, the partially closed conformation, 
observed with a single substrate, and the fully closed and active conformation, observed in the presence of 
both substrates (dTMP and ATP). In the 3D-structure described by Li de la Sierra et al. [11], TMPKmt is in the 
fully closed conformation despite the fact that the enzyme was cocrystallized as a complex with dTMP and 
SO42-, in the absence of ATP. Indeed, the structural characteristics observed around the ATP binding site are 
similar to those observed in crystal structures of TMPKy and TMPKec where ATP was fixed. The structural 
changes of TMPKmt occurring upon binding of the substrates and subsequent catalysis were elegantly 
investigated by X-ray experiments [23]. They were aligned with an induced-fit mechanism already suggested 
for several NMPKs [24, 25] and with the idea of an ordered bi-bi-catalytic mechanism, in contrast to the random 
bi-bi-mechanism generally proposed for these enzymes [26]. The possibility of a mechanism involving ATP 
binding first cannot be completely excluded from this study. However, it has been shown that dTMP exhibits an 
affinity (Km = 4.5 µM) for the enzyme more than 20 times stronger than ATP (Km 
Another unique feature of TMPKmt is that the magnesium ion lies in the dTMP-binding site. Instead of a NTP-
bound Mg
= 100 µM), suggesting that the 
pathway involving dTMP binding first is largely favored when both substrates are present in the same 
concentration [12]. Closure of the LID region upon ATP binding would sterically restrict the access of dTMP to 
its binding site or require a secondary channel through which dTMP may enter the active site.  
2+
 
 as typically found in NMPKs, it is coordinated by an oxygen atom from the phosphoryl group of 
dTMP, four water molecules and the carboxylate oxygen atoms of D9 and E166. This cation is supposed to 
neutralize the electrostatic repulsion between the anionic substrates and to act as a clamp for the proper 
alignment of the phosphoryl acceptor and donor.  
The dTMP-binding site of TMPKmt 
Examination of the X-ray structure of TMPKmt [11] reveals that the main binding forces between dTMP and the 
enzyme are the following (Fig. 2): (i) a stacking interaction between the pyrimidine ring and F70; (ii) a hydrogen 
bond between the O4 of thymine and the R74 side-chain, which results in a preference for thymine over 
cytosine; (iii) a hydrogen bond between N100 and the N3 of the thymine ring; (iv) a hydrogen bond between the 
3’-hydroxyl of dTMP and the terminal carboxyl of D9, that in turn interacts with the magnesium ion responsible 
for positioning the phosphate oxygen of dTMP. The 3’-OH group actually makes three polar contacts: one with 
a water molecule involved in the Mg2+-coordination and two others with D9; (v) hydrogen bonds between the 5’-
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O-phosphoryl and Y39, F36 and an ionic interaction with R95 and Mg2+
 
. Y39 makes two polar contacts with 
dTMP: one with the phosphate oxygen atom and the other one with the oxygen atom at the 5’-position. An 
arginine residue replaces this tyrosine in TMPKh; (vi) the presence of Y103 close to the 2’-position is believed 
to render the enzyme catalytically selective for 2’-deoxyribo-nucleotides versus ribonucleotides.  
These differences are potentially interesting starting points for finding inhibitors that exert selectivity for 
TMPKmt over TMPKh.  
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Fig. (2). Top: Schematic drawing of the dTMP (bulk lines) binding site of TMPKmt [11]. Bottom: Structure and 
atom numbering of dTMP. 
  
  
DESIGN OF INHIBITORS OF TMPKMT  
Initial structure-activity relationship  
The first modified dTMP analogs to have been reported are listed in Table 2 [12].  
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NMP  Kmapp
 
V(µM) m K(µmole/min/mg 
of protein) 
i
dTMP  
 (µM) 
40 10.60  
dUMP  2100 3.50  
5-Br-dUMP  33 9.82  
5-I-dUMP  140 7.46  
5-F-dUMP  420 4.66  
AZTMP    10 
5-methyl isodCMP 
O
OH
NN
H2N
2-O3PO
O
 
   
130 
 
Table 2. Kinetic parameters of base- and sugar-modified nucleotides for TMPKmt [12]. The affinity 
data were assessed at 340 nm via a spectrophotometric assay using coupling enzymes [27]. The 
concentration of ATP was kept constant at 0.5 mM. 
  
- Base modifications  
The 5-methyl group of dTMP was replaced by several halogen atoms [12]. The resulting analogs 
behave as substrates for TMPKmt, the best one being 5-Br-dUMP with a slight increase in affinity and 
negligible drop in velocity rate compared to dTMP (Table 2). Substitution by an iodine (5-I-dUMP) or a fluorine 
(5-F-dUMP) drastically decreased the affinity for the enzyme. X-ray crystallography showed that 5-I-dUMP 
binds to the phosphate acceptor binding site in a very similar fashion as dTMP [11]. Removal of the methyl 
group (dUMP) drastically affects the affinity (50-fold decrease) and the reaction rate (3-fold decrease). The 5-
halogenated deoxyuridines counterparts are competitive inhibitors of TMPKmt with affinities quite similar to 
their corresponding nucleoside monophosphates [28]. 5-Cl-dU and 5-Br-dU are remarkably specific for 
TMPKmt versus TMPKh.  
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- Sugar modification: AZTMP  
The 3’-hydroxyl group of dTMP, which adopts a C2’-endo conformation in the active site, participates in 
Mg2+
Substitution of the 3'-hydroxyl by an azido group affords AZTMP, which is a substrate for TMPKec [22] (with 
only a 2-fold reduction of k
 stabilization through interactions involving a water molecule and Asp9, the conserved acidic residue of the 
P-loop. Modifications of the 3’-position capable of destabilizing the interaction with the metal could form a firm 
basis to design compounds that specifically inhibit TMPKmt.  
cat
Interestingly, in the case of TMPKmt, the presence of an azido group completely suspends catalysis without 
changing the affinity. Thus, AZTMP behaves as a competitive inhibitor of TMPKmt with a K
), TMPKy [29, 30], as well as TMPKh [21, 31], although with a low efficiency for the 
latter two enzymes. TMPKh is involved in the activation of the anti-HIV prodrug AZT. Since the enzyme poorly 
phosphorylates AZTMP, this step forms a bottleneck in the activation pathway that contributes to the toxicity 
and limited efficacy of AZT therapy [29, 32].  
i value of 10 µM, its 
nucleosidic counterpart AZT exhibiting a Ki of 28 µM [12, 17]. AZTMP probably inhibits TMPKmt by preventing 
Mg2+ from binding. Based on X-ray structures of TMPKmt in complex with dTMP and AZTMP, Fioravantini et al. 
rationalized this hypothesis as follows [33]. In a first step along the reaction pathway, dTMP interacts with D163 
via an essential water molecule (Wat141). At this early stage of the reaction, the semi-open state of the enzyme 
prevents metal stabilization. In a second step, the LID region becomes organized as an α-helix, thereby 
favoring the stabilization of D9, the conserved P-loop residue, and leading to metal binding. When AZTMP 
binds to the enzyme, the azido group takes the place of Wat141, which is prevented from binding and cannot 
stabilize D163. Consequently, LID closure, believed to be promoted by the anchoring of D163 on the 
nucleotide, and Mg2+
 
 binding are not possible. Under these conditions, the only positively charged residue 
interacting with the acceptor phosphate is R95, which is insufficient to neutralize electrostatic repulsion 
between the anionic substrates dTMP and ATP. Additionally, the azido group establishes direct interactions 
with D9 before LID closure; therefore, D9, which also interacts with the α-phophate group, is locked in a 
catalytically incompetent position.  
TMPKmt inhibitors closely related to thymidine  
Based on the X-ray structure of TMPKmt and the known affinities for the enzyme of a few compounds 
described above, it was decided to establish preliminary structure-activity relationships (SAR) by evaluating a 
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series of nucleotides modified at the 2’- and 3’-positions or on the heterocyclic moiety of the dTMP-scaffold for 
their affinity toward TMPKmt. To address their selectivity, the most promising analogs were also evaluated for 
their affinity for TMPKh.  
 
- Base moiety modifications 
Because a 5-bromine (5Br-dUMP) is well accepted by the enzyme, analogs with sterically demanding 
substituents at the 5-position (e.g. a hydroxymethyl (5CH2OH-dUMP), an ethyl and a bromovinyl group, or a 
furanyl, a benzyloxymethyl or a thienyl group, aimed at forming a stacking interaction with F36) were 
synthesized utilizing known synthetic transformations [34]. These inhibitors were less potent indicating that the 
cavity near the 5-position cannot be stretched too much. However, introduction of smaller 5-substituents (5-
fluorine, 5-hydroxyl and 5-trifluoromethyl) also imparted reduced activity. The binding of compound 5CH2OH-
dUMP to TMPKmt was further characterized by X-ray crystallography (Fig. 3). The structure verified our 
expectation by showing an anticipated hydrogen bond between 5CH2OH-dUMP and a known water molecule 
(Wat12 in PDB entry 1G3U), as well as an unexpected binding mode with the hydroxyl group pointing toward 
the network of interactions between E6, R95, Y179, and S99. Both binding modes contributed to the 
rigidification of the dTMP binding pocket and explained why 5CH2
NH
O
ON
O
OH
OP-O
O-
O
HO
OH-dUMP is an inhibitor rather than a 
substrate, compared with 5-I-dUMP of comparable steric hindrance.  
 
 
Fig. (3). Structure of the 5CH2
 
OH-dUMP (left) and the network of interactions of this inhibitor in the 
active site of TMPKmt (right). 
Base-modified nucleosides (i.e. non-phosphorylated) were also explored: purine and pyrimidine nucleosides 
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and C-nucleosides [28]. The best inhibitors remain the 5-halogenated derivatives of dU (isosteric and 
isoelectronic substituents of the methyl group) exhibiting high selectivity for TMPKmt compared to TMPKh. 
 
- 2'-Modifications  
Near the 2’-position lies Y103, believed to be responsible for discrimination between ribo- and 
deoxyribonucleotides. Consonantly, introduction of an α-oriented 2’-hydroxyl group in dTMP negatively affected 
the affinity for TMPKmt, while the effect of a β-directed 2’-OH group was somewhat less detrimental. 
Interestingly, the same SAR was later observed upon introduction of a 2’-hydroxyl on the α- or β-face of AZT. 
dTMP decoration with an α-directed 2'-amine group, envisioned to interact with Y103 via a cation-π interaction 
[35], also caused a drop in affinity. To sort out the influence of the size and electronegativity of 2’-substituents 
on the affinity for TMPKmt, α-oriented fluorine and chlorine substituents were introduced in dTMP [36]. It could 
be expected that nucleotide analogs that exhibit an S-type conformation, similar to the one adopted by the 
furanose of dTMP in its complex to TMPKmt, would have a higher affinity than those that have to be forced into 
that configuration by the enzyme. Indeed the 2’-Cl dTMP exhibited appreciable affinity with a K i
  
 value of 19 µM. 
Modeling suggested that the introduction of the chlorine affects the position of the sugar ring in the active 
pocket. As a result the 2'-chlorine is believed to occupy the pocket where normally the 3'-hydroxyl group 
resides.   
- 3'-Modifications  
Due to the unique behavior of AZTMP towards TMPKmt in comparison to other TMPKs, 3'-
modifications in particular were considered to have potential for finding good and selective inhibitors. Because 
AZTMP interacts through its azido group with Asp9, we intended to establish an ionic interaction with Asp9 by 
introducing a 3'-amino group. However, upon reduction of AZTMP to the corresponding 3’-aminonucleotide, the 
K i value increased 20-fold, indicating that the 3’-amino group does not interact with Asp9 as strongly as 
AZTMP. Remarkably, an analog with a 3’-fluorine behaved as a substrate for the enzyme rather than an 
inhibitor [36]. A series of nucleosides were then synthesized, that were based on the former SAR study and 
combined a 3’-azido or 3’-amino modification with a 2’-halogen substituent [37]. However, these analogs 
displayed only moderate binding affinity for TMPKmt. To explain this trend, their solution state conformational 
features were investigated using NMR spectroscopy and pseudorotational analysis. It was concluded that 
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compounds of this series were strongly biased towards the Northern furanose ring conformation, whereas 
TMPKmt prefers the opposite Southern conformers.   
Inspired by the fact that AZTMP perturbed the induced fit mechanism normally adopted by the enzyme and 
prevented the magnesium ion from binding in the active site, other modifications at C-3’ that might produce 
similar effects, were considered. In the X-ray structure one could observe a cavity with the potential of 
accommodating larger substituents near the 3'-position. Hence, a series of 3’-C-branched-chain nucleotides 
were prepared (the 3’-C-hydroxymethyl (1), 3’-C-azidomethyl (2), 3’-C-aminomethyl (3) and 3’-C-fluoromethyl 
(4) derivatives of dTMP, scheme 1) [38]. These analogs were synthesized from a common key intermediate 
with judiciously chosen 5’- and 6’-O-protective groups (Scheme 1). 2',3’-Dideoxy-3’-branched chain analogs 
proved to be potent inhibitors of TMPKmt: within the series 3'-CH2NH2 (3), 3'-CH2N3 (2) and 3'-CH2F (4) 
nucleotides exhibited the highest affinities with K i
NH
O
ON
OO
O
OMe
6'
NH
O
ON
OR2
R1
1: R1 = OH, R2 = OPO32-
2: R1 = N3, R2 = OPO32-
3: R1 = NH2, R2 = OPO32-
4: R1 = F, R2 = OPO32-
5: R1 = OH, R2 = OH
6: R1 = N3, R2 = OH
7: R1 = NH2, R2 = OH
8: R1 = F, R2 = OH
 values of 10.5, 12, and 15 µM, respectively. These results 
confirmed that TMPKmt tolerates the introduction of sterically demanding substituents at the 3'-position. Ribo-
analogs experienced a significant drop in affinity, probably due to steric hindrance of Y103. Although the 5'-O-
phosphorylated compounds (1-4) had somewhat higher affinities for the enzyme, the parent nucleosides (5-8) 
generally exhibited affinities for TMPKmt in the same order of magnitude and displayed a superior selectivity 
profile versus TMPKh.   
 
Scheme 1. Preparation of the 3’-branched chain nucleotides (1-4) and their nucleosidic                                                 
counterparts (5-8) starting from a common key intermediate [38]. 
 
- Computational procedures 
Based on a restricted set of 47 inhibitors of TMPKmt modified on the 5-, 2’-, 3’- and 5’-positions of 
dTMP (described above), the groups of Gopalakrishnan and Desijaru have developed models either to perform 
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virtual screening [39] or 3D-QSAR analysis [40]. Both approaches take advantage of the solved 3D-structure of 
TMPKmt with dTMP [11]. In the first study, pharmacophore modeling and docking were carried out to define a 
composite screening model. Docking analysis confirmed the role of weak interactions in promoting enzyme 
selectivity toward deoxyribonucleotides. It also highlighted the importance of water-mediated cooperative 
networks and weak hydrogen bonds to ligand binding affinities. After its validation by screening a database of 
2,000 molecules containing the training set of 47 molecules, the model was used for the virtual screening of 
500,000 compounds. 186 molecules were further selected that could be categorized into five clusters [39]. 
Unfortunately, no binding data were reported. In the second study, different alignment methods were exploited 
to create molecular field analysis models. Again the same collection of 47 inhibitors of TMPKmt were selected 
either as the training or as the test set. One model out of three proved to be more predictive and was claimed 
informative about the chemical and structural features for TMPKmt inhibition [40].  
 
Drug design and identification of ‘non nucleosidic’ families 
With the aim to generate novel ligand families, a new fragment-based de novo drug design program was 
applied to the dTMP binding site of TMPKmt. This program called LEA3D combines 3D fragments and 
optimizes molecules by genetic algorithms [41]. It is associated to FlexX in order to evaluate the binding 
potency of the generated molecules. The active site of the enzyme was defined based on the coordinates of the 
3D-structure of the dTMP/TMPKmt complex (1G3U) [11]. The thymine moiety was used as the first building 
block as most of the key interactions with dTMP are established with this part of the molecule. Moreover, very 
few modifications of the base moiety have led to potent ligands of TMPKmt. Different design cycles yielded a 
compound in which the sugar and the phosphate moieties of dTMP were replaced by a substituted benzyl 
group (Scheme 2, R = -(CH2)2-CONH2
 
). A family of benzyl-thymine derivatives was derived from this 
compound and different members were synthesized [42, 43].  
NH
O
O
X
N
R   
Scheme 2. Left panel: Benzyl-thymine derivatives. X = CH3, Br, Cl; R = -(CH2)n-CONH2, -(CH2)n-COOH, -
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(CH2)n-OH. Right panel: superposition of the crystallographic dTMP (in orange) with the predicted binding 
mode of one derivative (X = CH3 and R = -(CH2)3
The general synthetic route involved a palladium-catalyzed coupling reactions between an appropriate p-iodo-
substituted benzyl pyrimidine and a suitably functionalized alkene or alkyne [42]. The arm length (n = 2-5), the 
saturation of the alkyl chain and the nature of the terminal function (amide, carboxylic acid or ester, alcohol) 
were varied. In the carboxylic series, the highest affinities (K
-COOH, in blue) using FlexX docking program (right) [41, 42]. 
i between 6.5 and 13 µM) were obtained for the C4 
compounds (n = 3), whereas in the amide series a C6 linker (n=5) was preferred. As previously noticed for 
nucleosidic inhibitors, the introduction of a bromine or a chloride at the 5-position improved the affinity of the 
benzyl derivatives. Some molecules showed moderate inhibitory potency on M. bovis (BCG strain) bacteria with 
MIC50
These results opened the way for a next generation of acyclic TMPKmt inhibitors (Scheme 3) that are 
accessible via a small number of synthetic steps [44]. 
 of 50 µg/mL, whereas no cototoxicity was observed up to 400 µg/mL [42].  
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HN
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XOO
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Scheme 3. Structures of the naphthalimide (left), naphtholactam (middle) and naphthosultam (right) series. X = 
CH3
 
 or Br [44].  
Initially, a set of analogs with different spacers connecting a distal 1,8-naphthalimide to the thymine moiety was 
tested enabling to select (Z)-butenyl derivative as a privileged linker (Ki = 1.9 and 1.1 µM for X=CH3 and Br 
respectively; Scheme 3, left part). Keeping this optimized spacer, the naphtalimide moiety was modified or 
substituted for a naphtholactam or a naphthosultam moiety (Scheme 3). A naphtholactam or a naphthosultam 
proved superior and yielded inhibitors with affinities in the submicromolar range (Ki = 0.42 and 0.27 µM, 
respectively). Interestingly, these compounds were shown to be very selective for TMPKmt versus TMPKh, 
consistent with the absence of cytotoxicity on Vero cells up to 100 µg/mL [44]. Unfortunately none of these 
compounds were able to significantly inhibit the growth of mycobacteria, probably due to their very poor 
solubility in culture media.  
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Serendipitous discovery and SAR of bicyclic nucleosides  
In an effort to further optimize the inhibitory potency of the 3'-C-branched-chain nucleosides, we envisoned to 
synthesize analogs of 7 with different substituents on the 3’-CH2-NH2 group. In an attempt to obtain a desired 
intermediate by simultaneous azide reduction and Barton deoxygenation at the 2’-position, some undesired 
compounds (Scheme 4) were obtained that, after deprotection, turned out to be potent and selective TMPKmt 
inhibitors (Ki
 
 of 3.5, 13.5 and 37 µM for 9, 10 and 11 respectively) [45].  
O
RO
T
O
N3
S
OPh
O
RO
T
NH2
O
RO
T
O
HN
S
O
RO
T
O
HN
O
a
b R = TBDMSR = H (9)
+ +
O
RO
T
NH
O
OR
T
NH
O
b R = TBDMSR = H (10) b
R = TBDMS
R = H (11)  
Scheme 4. Serendipitous discovery of TMPKmt inhibitors 9-11. Attempted simultaneous reduction of the azido 
function and Barton deoxygenation failed (a, R = TBDMS). Instead, three peculiar nucleoside analogs were 
formed, which proved active after removal of the silyl protective groups (b).  
 
Compound 9 was modeled into the crystal structure of TMPKmt (Fig. 4).
 
 
The six-membered ring, fused to the 
C-2', C-3'-bond of the sugar, apparently forces the 6'-nitrogen into the most appropriate position for interaction 
with D9. The sulphur atom experiences hydrophobic interactions with Y103 and Y165. When the sulphur atom 
in 9 is replaced by a smaller oxygen in 10, the cavity near the 3'-position is filled less efficiently, a result which 
is reflected in the somewhat lower affinity of 10.   
 17 
  
Fig. (4). Predicted binding mode of 9 with TMPKmt. A ribbon follows the backbone atoms of the 
enzyme. Hydrogen bonds are drawn as dashed lines. dTMP, as observed in the X-ray structure with 
TMPKmt, is shown in black sticks. Residues with atoms that make contact with 9, based on a Ligplot 
analysis, are F36, P37, L52, F70, R95, Y103 and Y165.  
 
Since the bicyclic nucleoside 9 formed an interesting lead for finding inhibitors with an improved fit in the 
enzyme cavity, various analogs (Scheme 5) were synthesized [46]. 
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Scheme 5. Attempted optimization of the bicyclic nucleoside lead 9. Structural variations are highlighted in red. 
 
In general, the accomplished modifications, such as replacement of the fused 6-membered thiocarbamate ring 
by a urea, thiourea or basic guanidine functionality (13, 12 and 14) or shrinking the 6-membered to a 5-
membered ring (15, 16), led to a slight drop in affinity. A notable exception was the replacement of the 5’-
CH2OH group by a methyl, yielding a compound (18) that was almost twice as active (Ki = 2.3 µM) as the 
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original lead 9. Because this deoxygenated bicyclic nucleoside is supposed to exhibit superior physico-
chemical properties for penetrating the lipophilic cell wall of M. tuberculosis, its in vitro inhibitory activity against 
M. bovis BCG was investigated. It showed 100% inhibition of bacterial growth at 100 µg/mL, while it did not 
demonstrate toxicity against VERO cell lines in a concentration range of 0–500 µg/mL. As compound 9 failed to 
show any inhibition of bacterial growth at 64 µg/mL, the activity of 18 represented significant progress.  
  
Optimization of the branched-chain nucleosides  
During the accidental formation of the bicyclic nucleosides, derivative 11, consisting of two 3’-branched 
thymidine units connected via a urea moiety, was also formed (Scheme 4). Due to the lack of a binding site for 
a second nucleoside at the 3'-position, the Ki
  
 value of 11 (37 µM) was most unexpected. A modeling 
experiment in GOLD showed that the sugar ring of the first monomer (I) binds in the dTMP pocket upside down, 
which enables hydrogen-bonding of its 5'-hydroxyl with D9 (Fig. 5).   
 
Fig. (5). Predicted binding mode with TMPKmt of 11 (color, I and II refer to the two monomers of 11) 
compared to the binding mode of dTMP (black sticks) as observed in the X-ray structure [11]. A ribbon 
follows the backbone atoms of the enzyme. Hydrogen bonds are drawn as dashed lines. Residues 
possessing atoms that make hydrophobic contact with 11, based on the Ligplot analysis, are K13, A35, 
Y39, F36, F70, R95, N100, Y103 and Y165.  
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This binding mode permits the sugar ring of the second monomer (II) to be directed toward the outside of the 
enzyme, where normally the phosphoryl donor binds. Experiments performed with dTMP or ATP showed that 
this dinucleoside is a competitive inhibitor not only for dTMP but also for ATP (Ki
The fact that the two nucleosides in 11 were bound via their 3'-positions made it a unique example of such a 
bisubstrate inhibitor, thereby paving the way for the design of much larger inhibitors of TMPKmt than explored 
so far. By synthesizing a series of substituted phenylthiourea derivatives of 3’-CH
 = 0.65 mM at 0.2 mM dTMP). 
These results are in agreement with the proposed binding mode. The low affinity of 11 for TMPKh (no inhibition 
at 1mM) indicated that the flexibility towards the orientation of the sugar ring is specific for TMPKmt.  
2NH2
 
-3’-dT, the possibility to 
occupy the binding site which accommodated the second thymidine residue of 11 with different aryl moieties 
was further explored [47]. Based on the second Topliss method [48], a small group of phenyl isothiocyanates 
was selected as reagents for the final derivatisation step. The inhibitory potency order of the resulting thiourea 
could then be compared to the tabulated potency order calculated for various parameter dependencies relating 
to lipophilic, electronic and steric effects. After deduction of the probable operative parameters from the 
observed activity pattern, new isothiocyanates were selected (Scheme 6). This resulted in several analogs with 
excellent affinity for TMPKmt, e.g. 19 (7.2 µM) and 20 (5 µM). 
O
NH2
NHN
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O
HO
NH
NHN
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O
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H
NR1
R2
1. suitable isothiocyanate, DMF
2. TBAF, THF
19:  R1 = Cl, R2 = Cl
20:  R1 = Cl, R2 = CF3 
Scheme 6. Synthesis of 3’-C-branched β-thioureaderivatives [47]. 
 
In a next step it was decided to explore if an alternative sugar scaffold could be used to impose the favorable 
relative orientation of the thymine and the phenylthiourea moieties for TMPKmt inhibition [47]. It was 
hypothesized that an α-nucleoside in which the 5’-position served as the thiourea anchor might show potential 
towards this end. This hypothesis was supported by the discovery that α-thymidine 5’-monophosphate (α-
dTMP) was accepted by TMPKmt as a substrate (Km = 15 µM), indicating that inversion of configuration at the 
anomeric position does not prevent the 5’-OP(O)(OH)2 moiety from being favorably oriented in order to operate 
as a phosphate acceptor. From a small library of 5’-N-arylthiourea derivatives, 22 (Fig. 6) emerged as one of 
the most potent TMPKmt inhibitors to date (Ki = 0.6 µM) [47]. Since it can be prepared in a limited number of 
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steps from the easily available α-thymidine, this compound represents a conceivably more attractive lead than 
the branched-chain nucleosides 19 and 20. Among the series of 5’-N-arylthiourea derivatives including 22, 
seven showed 40 to 50% inhibition of M. tuberculosis growth at 6 µg/mL, while demonstrating virtually no 
toxicity against VERO cell lines at a concentration up to 500 µg/mL [47]. Based on the observation that the 3’-
deoxy and the 3'-deoxy-2',3'-didehydro analogs of 22 exhibit slightly higher Ki values (2.3 and 3.8 µM), the 3’-
OH group is assumed to contribute to the overall affinity. Interestingly, the azido and amino precursors also 
caused TMPKmt inhibition with Ki 
 
values of 26 and 16 µM. These results can be rationalized by superimposing 
20 with the enzyme-bound conformation of 3’-branched chain nucleoside 7 (Fig. 6). Indeed, upon superposition 
of the thymine moieties, the 4’-aminomethyl moiety of 21 occupies the same space as the 3’-aminomethyl 
moiety of 7.   
O
HN
HO
NHN
O
O
R
21:  R = H
22:  R =
S
H
N Cl
CF3       
Fig. (6). Left panel: 5’-substituted α-thymidine derivatives. Right panel: superimposition of 21 (grey) 
with 7 (green) in the presumed enzyme-bound conformation. Note the similar orientation of the amino 
groups (in blue). 
 
A 3D pharmacophore mapping was performed by the groups of Andrade and Hopfinger based upon the 
application of receptor-independent (RI) 4D-QSAR formalism to the series of 5’-thiourea-substituted α-
thymidine derivatives. A set of 34 compounds including the dinucleoside 11 [47] were selected to develop 4D-
QSAR models [49]. Although the crystal structure of TMPKmt is available [11], the 3D structure of the receptor 
was neglected because of uncertainty in the binding mode of the ligands. One model out of ten was further 
considered and was shown to be 75% predictive on a test set of four compounds. Based on this model, 
Andrade et al. proposed regions to be further explored such as the 5’-arylthiourea moiety, such as the sugar-
pyrimidine ring structure and the region of the 5′-arylthiourea moiety. Moreover, this study highlighted the 
importance of lipophilic substituents on the 5′ -aryl moiety that possibly represent an additional pharmacophore 
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site responsible for the higher inhibition potency of these derivatives [49]. For a better validation of the model, 
this study has been expanded to a larger number of inhibitors of TMPKmt with more chemical diversity. 
Moreover, the autors will compare different subclasses of analog inhibitors, to map out subtle differences in 
binding pharmacophores for high potency inhibitors [50]. 
CONCLUSION  
The search for new antituberculosis drugs has rapidly expanded in the late 1990s thanks to the 
complete sequencing of the M. tuberculosis genome. The concomitant development of molecular genetics of M. 
tuberculosis and other mycobacteria has greatly facilitated target identification and validation. In this context, 
TMPKmt was chosen as a key enzyme in the metabolism of nucleotides. Even if TMPK is an ubiquitous 
enzyme, peculiar properties of TMPKmt came to light by biochemical and structural studies. A de novo design 
approach has afforded promising TMPKmt inhibitors with the required selectivity vis-à-vis the human enzyme, 
consistent with the absence of cytotoxicity of these compounds. The available X-ray structures proved a 
valuable tool to guide modifications of first series of nucleosidic compounds and to identify new families of 
inhibitors by in silico approaches. Different families of nucleosidic and non nucleosidic compounds were 
reported with Ki
 
 values in the micromolar and submicromolar range. Various analogues were able to inhibit 
mycobacterial growth, thereby validating TMPKmt as a new target for the search of new antituberculosis 
agents. However, up to now the MIC on mycobacterial cultures remains above the micromolar range (10 µM), 
probably due to uptake limitations. However, recent reports on potent and selective antimycobacterial activities 
for pyrimidine dideoxynucleosides featuring 5-alkynyl substituents [51] and nucleoside bisubstrate analogs [52] 
are encouraging and seem to suggest that further finetuning of the physicochemical properties may one day 
afford TMPK inhibitors with the expected antimycobacterial activity. 
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